Increased susceptibility to vaginal simian/human immunodeficiency virus transmission in pig-tailed macaques coinfected with Chlamydia trachomatis and Trichomonas vaginalis

Journal of Infectious Diseases

Volumn 210, Issue 8, 2014, Pages 1239-1247

  Henning, Tara R ^a   Butler, Katherine ^a   Hanson, Debra ^a   Sturdevant, Gail ^e   Ellis, Shanon ^d   Sweeney, Elizabeth M ^a   Mitchell, James ^a   Deyounks, Frank ^a   Phillips, Christi ^b   Farshy, Carol ^b   Fakile, Yetunde ^b   Papp, John ^b   Secor, W Evan ^c   Caldwell, Harlan ^e   Patton, Dorothy ^f   McNicholl, Janet M ^a   Kersh, Ellen N ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^b Division of STD Prevention   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^d Total Solutions Inc Inc   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^f UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

Chlamydia; HIV risk; HIV susceptibility model; Macaque; Menstrual cycle; STI or STD; Trichomonas

Indexed keywords

GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; INTERLEUKIN 6; VIRUS RNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHLAMYDIASIS; CONTROLLED STUDY; FEMALE; FEMALE GENITAL TRACT INFLAMMATION; INFECTION RISK; INFECTION SENSITIVITY; MACACA NEMESTRINA; MENSTRUAL CYCLE; MIXED INFECTION; NONHUMAN; PRIORITY JOURNAL; SEXUALLY TRANSMITTED DISEASE; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; TRICHOMONIASIS; VIREMIA; VIRUS TRANSMISSION; ANIMAL; CHLAMYDIA; CHLAMYDIA TRACHOMATIS; COLPOSCOPY; DISEASE TRANSMISSION; HIV RISK; HIV SUSCEPTIBILITY MODEL; IMMUNOLOGY; MACACA; MICROBIOLOGY; PARASITOLOGY; PATHOLOGY; PHYSIOLOGY; RISK FACTOR; SIMIAN IMMUNODEFICIENCY VIRUS; STI OR STD; TRICHOMONAS; TRICHOMONAS VAGINALIS; UTERINE CERVIX; VIROLOGY;

CHLAMYDIA; HIV RISK; HIV SUSCEPTIBILITY MODEL; MACAQUE; MENSTRUAL CYCLE; STI OR STD; TRICHOMONAS;

ANIMALS; CERVIX UTERI; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; COINFECTION; COLPOSCOPY; FEMALE; MACACA NEMESTRINA; RISK FACTORS; SEXUALLY TRANSMITTED DISEASES; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SIMIAN IMMUNODEFICIENCY VIRUS; TRICHOMONAS VAGINALIS; TRICHOMONAS VAGINITIS;

EID: 84910015088     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/jiu240     Document Type: Article

References (46)

1. Cohen MS. Sexually transmitted diseases enhance HIV transmission: no longer a hypothesis. Lancet 1998;351(suppl 3):5-7.
2. Gray RH, Wawer MJ, Sewankambo NK, et al. Relative risks and population attributable fraction of incident HIV associated with symptoms of sexually transmitted diseases and treatable symptomatic sexually transmitted diseases in Rakai District, Uganda. Rakai Project Team. AIDS 1999;13:2113-23.
3. Laga M, Manoka A, Kivuvu M, et al. Non-ulcerative sexually transmitted diseases as risk factors for HIV-1 transmission in women: results from a cohort study. AIDS 1993;7:95-102.
4. Quinn TC. STDs, viral load, circumcision, and the transmission of HIV. In: Braun JF, Horn T, eds. The PRN handbook. New York City: Physicians Research Network, 2000.
5. Sexton J, Garnett G, Rottingen JA. Metaanalysis and metaregression in interpreting study variability in the impact of sexually transmitted diseases on susceptibility to HIV infection. Sex Transm Dis 2005;32:351-7.
6. World Health Organization (WHO). Global Prevalence and Incidence of Selectable Curable Sexually Transmitted Infections Overview and Estimates. www.who.int/hiv/pub/sti/who-hiv-aids-2001.02.pdf. Accessed 13 November 2012.
7. Lifson JD, Haigwood NL. Lessons in nonhuman primate models for AIDS vaccine research: from minefields to milestones. Cold Spring Harb Perspect Med 2012;2:a007310.
8. Centers for Disease Control and Prevention. Interim guidance: preexposure prophylaxis for the prevention of HIV infection in men who have sex with men. MMWR 2011;60:65-8.
9. Microbicide Trials Network. MTN statement on decision to discontinue use of Tenofovir gel in VOICE, a major HIV prevention study in women. http://www.mtnstopshiv.org/node/3909. Accessed 21 May 2013.
10. Microbicide Trials Network. MTN statement on decision to discontinue use of oral Tenofovir tablets in VOICE, a major HIV prevention study in women. http://www.mtnstopshiv.org/node/3619. Accessed 21 May 2013.
11. Van Damme L, Corneli A, Ahmed K, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med 2012;367:411-22.
12. Parikh UM, Dobard C, Sharma S, et al. Complete protection from repeated vaginal simian-human immunodeficiency virus exposures in macaques by a topical gel containing tenofovir alone or with emtricitabine. J Virol 2009;83:10358-65.
13. Radzio J, Aung W, Holder A, et al. Prevention of vaginal SHIV transmission in macaques by a coitally-dependent Truvada regimen. PLoS One 2012;7:e50632.
14. Vishwanathan SA, Guenthner PC, Lin CY, et al. High susceptibility to repeated, low-dose, vaginal SHIV exposure late in the luteal phase of the menstrual cycle of pigtail macaques. J Acquir Immune Defic Syndr 2011;57:261-4.
15. Kersh E, Henning T, Vishwanathan SA, et al. SHIV Susceptibility Changes during the Menstrual Cycle of Pigtail Macaques. J Med Primatol 2014. In press. doi:10.1111/jmp. 12124.
16. Dobard C, Sharma S, Martin A, et al. Durable protection from vaginal simian-human immunodeficiency virus infection in macaques by tenofovir gel and its relationship to drug levels in tissue. J Virol 2012;86:718-25.
17. Dobard C, Sharma S, Parikh UM, et al. Postexposure protection of macaques from vaginal SHIV infection by topical integrase inhibitors. Sci Transl Med 2014;6:227ra35.
18. Smith JM, Rastogi R, Teller RS, et al. Intravaginal ring eluting tenofovir disoproxil fumarate completely protects macaques from multiple vaginal simian-HIV challenges. Proc Natl Acad Sci U S A 2013;110:16145-50.
19. Henning T, Fakile Y, Phillips C, et al. Development of a pigtail macaque model of sexually transmitted infection/HIV coinfection using Chlamydia trachomatis, Trichomonas vaginalis, and SHIV (SF162P3). J Med Primatol 2011;40:214-23.
20. Crostarosa F, Aravantinou M, Akpogheneta OJ, et al. A macaque model to study vaginal HSV-2/immunodeficiency virus co-infection and the impact of HSV-2 on microbicide efficacy. PLoS One 2009;4:e8060.
21. Patton DL, Cosgrove-Sweeney Y, Agnew K, Hillier SL. Concurrent STI: development of a macaque model for C.trachomatis and T. vaginalis infections. In: Proceedings of the Eleventh International Symposium on Human Chlamydial Infections, Niagara-on-the-Lake, Canada, 2006:417-20.
22. Patton DL, Sweeney YT, Agnew KJ, Balkus JE, Rabe LK, Hillier SL. Development of a nonhuman primate model for Trichomonas vaginalis infection. Sex Transm Dis 2006;33:743-6.
23. Patton DL, Sweeney YT, Paul KJ. A summary of preclinical topical microbicide rectal safety and efficacy evaluations in a pigtailed macaque model. Sex Transm Dis 2009;36:350-6.
24. Patton D, Butler K, Cosgrove-Sweeney YT, Tsai CC, Doncel G, Saifuddon M. Chlamydia trachomatis plus SHIV: co-infection model development in the pigtailed macaque. In: Chernesky M, ed. Chlamydia infections. Ontario, Canada: Elsevier Biomedical Press, 2006:412-24.
25. Plummer FA, Simonsen JN, Cameron DW, et al. Cofactors in malefemale sexual transmission of human immunodeficiency virus type 1. J Infect Dis 1991;163:233-9.
26. Royce RA, Sena A, Cates W Jr, Cohen MS. Sexual transmission of HIV. N Engl J Med 1997;336:1072-8.
27. Darville T, Hiltke TJ. Pathogenesis of genital tract disease due to Chlamydia trachomatis. J Infect Dis 2010;201(suppl 2):S114-25.
28. Marks E, Tam MA, Lycke NY. The female lower genital tract is a privileged compartment with IL-10 producing dendritic cells and poor Th1 immunity following Chlamydia trachomatis infection. PLoS Pathog 2010;6:e1001179.
29. Spear GT, Kendrick SR, Chen HY, et al. Multiplex immunoassay of lower genital tract mucosal fluid from women attending an urban STD clinic shows broadly increased IL1ss and lactoferrin. PLoS One 2011;6:e19560.
30. Thurman AR, Doncel GF. Innate immunity and inflammatory response to Trichomonas vaginalis and bacterial vaginosis: relationship to HIV acquisition. Am J Reprod Immunol 2011;65:89-98.
31. Ficarra M, Ibana JS, Poretta C, et al. A distinct cellular profile is seen in the human endocervix during Chlamydia trachomatis infection. Am J Reprod Immunol 2008;60:415-25.
32. Gondek DC, Olive AJ, Stary G, Starnbach MN. CD4+ T cells are necessary and sufficient to confer protection against Chlamydia trachomatis infection in the murine upper genital tract. J Immunol 2012;189:2441-9.
33. Kaul R, Pettengell C, Sheth PM, et al. The genital tract immune milieu: an important determinant of HIV susceptibility and secondary transmission. J Reprod Immunol 2008;77:32-40.
34. Schust DJ, Ibana JA, Buckner LR, et al. Potential mechanisms for increased HIV-1 transmission across the endocervical epithelium during C.trachomatis infection. Curr HIV Res 2012;10:218-27.
35. Blakley GB, Beamer TW, Dukelow WR. Characteristics of the menstrual cycle in nonhuman primates. IV. Timed mating in Macaca nemestrina. Lab Anim 1981;15:351-3.
36. Castle PE, Rodriguez AC, Bowman FP, et al. Comparison of ophthalmic sponges for measurements of immune markers from cervical secretions. Clin Diagn Lab Immunol 2004;11:399-405.
37. Otten RA, Adams DR, Kim CN, et al. Multiple vaginal exposures to low doses of R5 simian-human immunodeficiency virus: strategy to study HIV preclinical interventions in nonhuman primates. J Infect Dis 2005;191:164-73.
38. Subbarao S, Otten RA, Ramos A, et al. Chemoprophylaxis with tenofovir disoproxil fumarate provided partial protection against infection with simian human immunodeficiency virus in macaques given multiple virus challenges. J Infect Dis 2006;194:904-11.
39. Holm S. A simple sequentially rejective multiple test procedure. J Scand Stat 1979;6:65-70.
40. Poli G, Bressler P, Kinter A, et al. Interleukin 6 induces human immunodeficiency virus expression in infected monocytic cells alone and in synergy with tumor necrosis factor alpha by transcriptional and posttranscriptional mechanisms. J Exp Med 1990;172:151-8.
41. Breen EC, Rezai AR, Nakajima K, et al. Infection with HIV is associated with elevated IL-6 levels and production. J Immunol 1990;144:480-4.
42. Spear GT, Zariffard MR, Chen HY, et al. Positive association between HIV RNA and IL-6 in the genital tract of Rwandan women. AIDS Res Hum Retroviruses 2008;24:973-6.
43. Cocchi F, De Vico AL, Garzino-Demo A, Arya SK, Gallo RC, Lusso P. Identification of RANTES, MIP-1 alpha, and MIP-1 beta as the major HIV-suppressive factors produced by CD8+ T cells. Science 1995;270:1811-5.
44. Fichorova RN, Lee Y, Yamamoto HS, et al. Endobiont viruses sensed by the human host - beyond conventional antiparasitic therapy. PLoS One 2012;7:e48418.
45. Garcia-Lerma JG, Aung W, Cong ME, et al. Natural substrate concentrations can modulate the prophylactic efficacy of nucleotide HIV reverse transcriptase inhibitors. J Virol 2011;85:6610-7.
46. Chenine AL, Shai-Kobiler E, Steele LN, et al. Acute Schistosoma mansoni infection increases susceptibility to systemic SHIV clade C infection in rhesus macaques after mucosal virus exposure. PLoS Negl Trop Dis 2008;2:e265.